Gabriella Orlando

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4593343/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Long-Term Impact of the COVID-19 Pandemic on In-Hospital Antibiotic Consumption and Antibiotic Resistance: A Time Series Analysis (2015–2021). Antibiotics, 2022, 11, 826.	3.7	21
2	Ceftazidime/avibactam and ceftolozane/tazobactam for the treatment of extensively drug-resistant Pseudomonas aeruginosa post-neurosurgical infections: three cases and a review of the literature. Infection, 2021, 49, 549-553.	4.7	17
3	Hypokalemia in Patients with COVID-19. Clinical and Experimental Nephrology, 2021, 25, 401-409.	1.6	78
4	Twenty-four-hour serum creatinine variation is associated with poor outcome in the novel coronavirus disease 2019 (COVID-19) patients. Kidney Research and Clinical Practice, 2021, 40, 231-240.	2.2	14
5	The impact of tocilizumab on respiratory support states transition and clinical outcomes in COVID-19 patients. A Markov model multi-state study. PLoS ONE, 2021, 16, e0251378.	2.5	3
6	Better prognosis in females with severe COVID-19 pneumonia: possible role of inflammation as potential mediator. Clinical Microbiology and Infection, 2021, 27, 1137-1144.	6.0	15
7	Herpes Simplex Virus Re-Activation in Patients with SARS-CoV-2 Pneumonia: A Prospective, Observational Study. Microorganisms, 2021, 9, 1896.	3.6	28
8	Development of post-COVID-19 cardiovascular events: an analysis of clinical features and risk factors from a single hospital retrospective study. Infezioni in Medicina, 2021, 29, 538-549.	1.1	3
9	COVID-19-associated vasculitis and thrombotic complications: from pathological findings to multidisciplinary discussion. Rheumatology, 2020, 59, e147-e150.	1.9	19
10	Epidemiology and Outcomes of Bloodstream Infections in HIV-Patients during a 13-Year Period. Microorganisms, 2020, 8, 1210.	3.6	6
11	A Retrospective Whole-Genome Sequencing Analysis of Carbapenem and Colistin-Resistant Klebsiella pneumoniae Nosocomial Strains Isolated during an MDR Surveillance Program. Antibiotics, 2020, 9, 246.	3.7	12
12	Tocilizumab in patients with severe COVID-19: a retrospective cohort study. Lancet Rheumatology, The, 2020, 2, e474-e484.	3.9	772
13	Machine learning in predicting respiratory failure in patients with COVID-19 pneumonia—Challenges, strengths, and opportunities in a global health emergency. PLoS ONE, 2020, 15, e0239172.	2.5	43
14	Significant chronic airway abnormalities in neverâ€smoking <scp>HIV</scp> â€infected patients. HIV Medicine, 2019, 20, 657-667.	2.2	14
15	Re: Lebentrau S, Gilfrich C, Vetterlein MW, Schumacher H, Spachmann PJ, Brookman-May SD, Fritsche HM, Schostak M, Wagenlehner F, Burger M, May M, MR2 study group (2017) Impact of the medical specialty on knowledge regarding multidrug-resistant organisms and strategies toward antimicrobial stewardship. Int Urol Nephrol 49:1311–1318. International Urology and Nephrology. 2018. 50. 873-874.	1.4	0
16	Independent association of subclinical coronary artery disease and emphysema in <scp>HIV</scp> â€infected patients. HIV Medicine, 2016, 17, 178-187.	2.2	12
17	Antimicrobial stewardship in a Gastroenterology Department: Impact on antimicrobial consumption, antimicrobial resistance and clinical outcome. Digestive and Liver Disease, 2016, 48, 1142-1147.	0.9	22
18	Switching to darunavir/ritonavir monotherapy vs. triple-therapy on body fat redistribution and bone mass in HIV-infected adults: the Monarch randomized controlled trial. International Journal of STD and AIDS, 2014, 25, 207-212	1.1	13

GABRIELLA ORLANDO

#	Article	IF	CITATIONS
19	Gender differences in GH response to GHRH+ARG in lipodystrophic patients with HIV: a key role for body fat distribution. European Journal of Endocrinology, 2014, 170, 685-696.	3.7	10
20	The natural history of <scp>HIV</scp> â€essociated lipodystrophy in the changing scenario of <scp>HIV</scp> infection. HIV Medicine, 2014, 15, 587-594.	2.2	26
21	The Burden of Image Based Emphysema and Bronchiolitis in HIV-Infected Individuals on Antiretroviral Therapy. PLoS ONE, 2014, 9, e109027.	2.5	27
22	Inverse Correlation Between Vascular Calcification and Bone Mineral Density in Human Immunodeficiency Virus-Infected Patients. Calcified Tissue International, 2013, 93, 413-418.	3.1	8
23	Randomized Trial to Evaluate Cardiometabolic and Endothelial Function in Patients with Plasma HIV-1 RNA Suppression Switching to Darunavir/Ritonavir with or without Nucleoside Analogues. HIV Clinical Trials, 2013, 14, 140-148.	2.0	14
24	Cost of noninfectious comorbidities in patients with HIV. ClinicoEconomics and Outcomes Research, 2013, 5, 481.	1.9	46
25	Combined Use of Waist and Hip Circumference to Identify Abdominally Obese HIV-Infected Patients at Increased Health Risk. PLoS ONE, 2013, 8, e62538.	2.5	7
26	GH response to GHRH plus arginine is impaired in lipoatrophic women with human immunodeficiency virus compared with controls. European Journal of Endocrinology, 2012, 166, 415-424.	3.7	14
27	Long-Term Efficacy and Safety of Polyacrylamide Hydrogel Injection in the Treatment of Human Immunodeficiency Virus–Related Facial Lipoatrophy. Plastic and Reconstructive Surgery, 2012, 129, 101-109.	1.4	25
28	Parallel increase of subclinical atherosclerosis and epicardial adipose tissue in patients with HIV. American Heart Journal, 2012, 163, 1024-1030.	2.7	27
29	Ectopic Fat is Linked to Prior Cardiovascular Events in Men With HIV. Journal of Acquired Immune Deficiency Syndromes (1999), 2012, 59, 494-497.	2.1	42
30	Progression of coronary artery calcium in men affected by human immunodeficiency virus infection. International Journal of Cardiovascular Imaging, 2012, 28, 935-941.	1.5	26
31	Erectile Dysfunction is Not a Mirror of Endothelial Dysfunction in HIV-Infected Patients. Journal of Sexual Medicine, 2012, 9, 1114-1121.	0.6	18
32	High-density Hyaluronic Acid for the Treatment of HIV-related Facial Lipoatrophy. Aesthetic Plastic Surgery, 2012, 36, 180-185.	0.9	13
33	Premature Age-Related Comorbidities Among HIV-Infected Persons Compared With the General Population. Clinical Infectious Diseases, 2011, 53, 1120-1126.	5.8	1,044
34	Morphological and Metabolic Components of Lipodystrophy in Various Nevirapine-Based Highly Active Antiretroviral Therapy (HAART) Regimens. Clinical Drug Investigation, 2011, 31, 759-767.	2.2	2
35	Premature Decline of Serum Total Testosterone in HIV-Infected Men in the HAART-Era. PLoS ONE, 2011, 6, e28512.	2.5	116
36	Surgical correction of HIV-associated facial lipoatrophy. Aids, 2011, 25, 1-12.	2.2	28

GABRIELLA ORLANDO

#	Article	IF	CITATIONS
37	Human Immunodeficiency Virus Is the Major Determinant of Steatosis and Hepatitis C Virus of Insulin Resistance in Virus-associated Fatty Liver Disease. Archives of Medical Research, 2011, 42, 690-697.	3.3	22
38	Vitamin D deficiency is associated with type 2 diabetes mellitus in HIV infection. Aids, 2011, 25, 525-529.	2.2	32
39	Epicardial adipose tissue is an independent marker of cardiovascular risk in HIV-infected patients. Aids, 2011, 25, 1199-1205.	2.2	52
40	Human immunodeficiency virus infection is associated with accelerated atherosclerosis. Journal of Antimicrobial Chemotherapy, 2011, 66, 1857-1860.	3.0	16
41	Hypertriglyceridemia and Waist Circumference Predict Cardiovascular Risk among HIV Patients: A Cross-Sectional Study. PLoS ONE, 2011, 6, e25032.	2.5	24
42	Upregulation of nuclear-encoded mitochondrial LON protease in HAART-treated HIV-positive patients with lipodystrophy: implications for the pathogenesis of the disease. Aids, 2010, 24, 841-850.	2.2	35
43	Nonalcoholic Fatty Liver Disease in HIV-Infected Persons: Epidemiology and the Role of Nucleoside Reverse Transcriptase Inhibitors. Journal of Acquired Immune Deficiency Syndromes (1999), 2010, 53, 278.	2.1	6
44	Lipodystrophy and anti-retroviral therapy as predictors of sub-clinical atherosclerosis in human immunodeficiency virus infected subjects. Atherosclerosis, 2010, 208, 222-227.	0.8	61
45	Coronary Aging in HIVâ€Infected Patients. Clinical Infectious Diseases, 2009, 49, 1756-1762.	5.8	106
46	Viral hepatitis is associated with reduced bone mineral density in HIV-infected women but not men. Aids, 2009, 23, 2191-2198.	2.2	33
47	Metabolic disorders induced by highly active antiretroviral therapy and their relationship with vascular remodeling of the brachial artery in a population of HIV-infected patients. Metabolism: Clinical and Experimental, 2009, 58, 927-933.	3.4	7
48	Hyperhomocysteinaemia in HIVâ€infected patients: determinants of variability and correlations with predictors of cardiovascular disease. HIV Medicine, 2009, 10, 28-34.	2.2	12
49	The Role of the Framingham Risk Score to Predict the Presence of Subclinical Coronary Atherosclerosis in Patients with HIV Infection. Journal of Acquired Immune Deficiency Syndromes (1999), 2009, 52, 303-304.	2.1	7
50	Detectable HIV Viral Load Is Associated With Metabolic Syndrome. Journal of Acquired Immune Deficiency Syndromes (1999), 2009, 52, 459-464.	2.1	27
51	Glomerular filtration rates in HIV-infected patients treated with and without tenofovir: a prospective, observational study. Journal of Antimicrobial Chemotherapy, 2008, 63, 374-379.	3.0	15
52	Reply to Remtulla and Decker. Clinical Infectious Diseases, 2008, 47, 1234-1234.	5.8	0
53	Nonalcoholic Fatty Liver Disease in HIVâ€Infected Patients Referred to a Metabolic Clinic: Prevalence, Characteristics, and Predictors. Clinical Infectious Diseases, 2008, 47, 250-257.	5.8	208
54	Mitochondrial DNA Haplogroups and Highly Active Antiretroviral Therapy–Related Lipodystrophy. Clinical Infectious Diseases, 2008, 47, 962-968.	5.8	26

GABRIELLA ORLANDO

#	Article	IF	CITATIONS
55	Severity of Lipodystrophy Is Associated with Decreased Health-Related Quality of Life. AIDS Patient Care and STDs, 2008, 22, 577-585.	2.5	41
56	Prevalence of and Risk Factors for Pubic Lipoma Development in HIV-Infected Persons. Journal of Acquired Immune Deficiency Syndromes (1999), 2007, 45, 72-76.	2.1	14
57	Sexual dysfunction in HIV-infected men: role of antiretroviral therapy, hypogonadism and lipodystrophy. Antiviral Therapy, 2007, 12, 1059-65.	1.0	15
58	Sexual Dysfunction in HIV-Infected Men: Role of Antiretroviral Therapy, Hypogonadism and Lipodystrophy. Antiviral Therapy, 2007, 12, 1059-1066.	1.0	54
59	Multidisciplinary Approach to the Treatment of Metabolic and Morphologic Alterations of HIV-Related Lipodystrophy. HIV Clinical Trials, 2006, 7, 97-106.	2.0	45
60	Facial Lipohypertrophy in HIV-Infected Subjects Who Underwent Autologous Fat Tissue Transplantation. Clinical Infectious Diseases, 2005, 40, e13-e15.	5.8	52
61	Comparison of three different interventions for the correction of HIV-associated facial lipoatrophy: a prospective study. Antiviral Therapy, 2005, 10, 753-9.	1.0	10
62	Comparison of Three Different Interventions for the Correction of HIV-Associated Facial Lipoatrophy: A Prospective Study. Antiviral Therapy, 2005, 10, 753-759.	1.0	58
63	Morphologic Alterations in HIV-Infected People with Lipodystrophy Are Associated with Good Adherence to HAART. HIV Clinical Trials, 2003, 4, 99-106.	2.0	38